



# A STRATEGIC INVESTMENT IN TRIPLE HAIR'S INNOVATIVE HAIR LOSS SOLUTIONS

A BIOTECHNOLOGY COMPANY DEVELOPING INNOVATIVE  
THERAPIES FOR ALOPECIA

**Jean-Philippe Gravel, MBA**  
CEO






## FORWARD-LOOKING STATEMENT

This presentation contains forward-looking statements that reflect the current expectations regarding future events. There's a risk that expectations, and the forward-looking statements on which they are based, will not prove to be accurate.



# MARKET OPPORTUNITY

People Love Their Hair: Paying Despite  
Low Drug Efficacy




The global hair loss treatment market was valued at \$8.76 billion in 2023 and is expected to grow to \$16 billion by 2030, driven by rising consumer awareness and the demand for effective solutions.



Despite the market's size, current prescription treatments often fail to meet expectations due to side effects and limited efficacy.

# CHALLENGE


Current Therapies Address Just Part Of  
The Problem



SOLUTION

Novel Patented Combination  
Addressing Multiple Pathways

Triple Combination Therapy = TH07





# TH07 STORY

Dr. Houfar Sekhavat, Founder  
Ophthalmologist & Researcher

## Suffering from Hair Loss

The development of TH07, Triple Hair's patented triple combination, began with the personal journey of founder Dr. Houfard Sekhavat, who experienced androgenic alopecia firsthand.

## Observed Latanoprost Efficacy on Eyelash Hair Growth

Recognizing the growth potential of latanoprost in the early 2010s on his patient eyelashes, Dr. Sekhavat, an ophthalmologist, embarked on creating a new treatment.

## Tested Combination of Various Concentrations of the 3 Drugs

Through extensive research and testing, TH07 formula was selected for further studies considering its potential efficacy and safety profile.

## 6-month treatment with TH07



# TH07 PROOF OF CONCEPT TRIAL

More Hair Growth And Satisfactory  
Results With TH07



Drug Name	Regrowth Levels			
	Regrowth	Dense	Moderate	Minimal
TH07 Triple Combination	100%	✓	✓	✓
Finasteride 0,1%	50%	✗	✓	✓
Latanoprost 0.03%	33%	✗	✗	✓
Minoxidil 5%	25%	✗	✗	✓

A 6-month Randomized, Single-blind, Active Controlled Trial conducted on 40 participants in Canada by an independent investigator.



# TH07 TREATMENT

Before and After Photos



**Dr Houfar Sekhavat**


Result after 6 months of use



Patient Result as part of  
**Phase 2 Clinical Trial**



**Patient in his late twenties**  
using Compounded TH07






# HUMAN RESOURCES

Experienced Teams with Proven Track Record



-  Seasoned Advisory Board Members
-  Highly Experienced C-Suite Team with Solid Network
-  Consultants and Life Science Incubators Support

-  Agreement with Manufacturing and CRO Partners
-  Strong Group of Clinical Investigators





# BOARD OF DIRECTORS

Seasoned Advisory Board Members



**Houfar Sekhavat, MD**  
Founder and Chairman

- A renowned ophthalmologist with over 19 years of experience (since 2005).
- Actively involved in both medicine and research on the international stage.



**Jean-Philippe Gravel, MBA**  
President, CEO and Director

- Secured financing and negotiated partnerships for four biotechnology and natural product companies.
- Expertise spans both private and public sectors.



**Luc Tanguay**  
Director President of the Audit Committee

- Over 20 years of experience in the biotechnology industry.
- Former senior manager and board member of Theratechnologies (TSX: TH, NASDAQ: THTX)



**Robert Y. Girard**  
Director President of the Governance Committee

- Partner at Fasken Martineau DuMoulin LLP since 2001, focusing on mergers & acquisitions and business law.
- Served on the boards of Global Diversified Investment Grade Income Trust, Global Diversified Investment Grade Income Trust II, and Theratechnologies.



**Denis Albert, CA, CPA**  
Director

- Partner at MNP LLP and, previously Managing Partner at Boudreau Albert Savoie & Associates.
- Over 24 years of experience in accounting, tax planning, and business matters, including restructuring and acquisitions.



# EXECUTIVE TEAM



**Chanèle Dumontier, CPA**  
Chief Financial Officer

- Extensive finance and accounting experience in leading international companies, focusing on growth strategies, mergers, acquisitions, and partnerships.
- Strong business modeling and deal-making skills, enabling creative solutions and value maximization.
- Excellent team player, effectively rallying the team to achieve company objectives.



**Jean Lachapelle, M. Sc.**  
VP Marketing & BD

- Over 20 years in Commercial Operations in big pharma.
- Co-founded PACE Pharmaceuticals up to successful exit after 4 years.
- Over 10 years in consulting biotechnology SMEs.



**Houfar Sekhavat, MD**  
Founder and Chairman

- A renowned ophthalmologist with over 19 years of experience (since 2005).
- Actively involved in both medicine and research on the international stage.



**Jean-Philippe Gravel, MBA**  
President, CEO and Director

- Secured financing and negotiated partnerships for four biotechnology and natural product companies.
- Expertise spans both private and public sectors.




**Satish Asotra, Ph.D., MBA**  
Chief Scientific Officer

- Held multiple executive positions with major international pharmaceutical companies.
- Contributes to sustained growth through skills, innovative spirit, and process optimization.
- Well-versed in Lean development and Six Sigma practices; dynamic, versatile, and possesses strong management skills.



PIPELINE



PRESCRIPTION PRODUCTS

CANDIDATE	INDICATION	DEVELOPMENT	CLINICAL	APPROBATION	COMMERCIALIZATION
TH07	MEN Androgenic Alopecia	PHASE 3			2027-2028
TH21	FEMALE Pattern Baldness	DOSE RANGING			2028-2029
TH34	MEN Beard	FORMULATION			2028-2030
TH45	FEMALE Lash & Brow	FORMULATION			2028-2030

OTC PRODUCTS

CANDIDATE	INDICATION	DEVELOPMENT	CLINICAL	APPROBATION	COMMERCIALIZATION
TH16	MEN Androgenic Alopecia	AVAILABLE FOR DISTIBUTION UNDER RIZN BRAND OR WHITE LABEL			
TH17	FEMALE Pattern Baldness	AVAILABLE FOR DISTIBUTION UNDER PLENTY NATURAL BRAND OR WHITE LABEL			





## JOIN US to Disrupt The Hair Loss Prescription Market

**Jean-Philippe Gravel, MBA**

President and Chief Executive Officer

514-804-4569

[jpgravel@triplehair.ca](mailto:jpgravel@triplehair.ca)

**Jean Lachapelle, M. Sc.**

V.P. Business Development & Marketing

514-824-7223

[jlachapelle@triplehair.ca](mailto:jlachapelle@triplehair.ca)

